SCHEMBL2028883

SCHEMBL2028883

COc1cc(C(OC(=O)C(Cl)(Cl)Cl)c2ccccc2)c([N+](=O)[O-])cc1OC

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.45
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
MAPT P10636 5/20 0.42
GAA P10253 1/20 0.42
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 5/20 0.40
TDP1 Q9NUW8 2/20 0.40
HTT P42858 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
CYP3A4 P08684 2/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
CYP2C19 P33261 1/20 0.39
HPGD P15428 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP19A1 P11511 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5583404 0.89 ALDH1A1 (0.41) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL2029343 0.85 MAPT (0.46) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL5583455 0.82 HCAR3 (0.41) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL5583445 0.82 PKM (0.40) LMNAMEN1KMT2AMAPTGAA
SCHEMBL5583271 0.82 CYP1A2 (0.48) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL2034278 0.81 MAPT (0.41) LMNAMEN1KMT2AMAPTALDH1A1
SCHEMBL2029622 0.81 MAPT (0.43) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL2029916 0.81 CYP1A2 (0.37) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL2035185 0.81 CYP1A2 (0.39) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL5583275 0.80 MAPT (0.41) LMNAMEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956011-B2 Materials and methods for the photodirected synthesis of oligonucleotide arrays THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2011-06-07 US disclosed
US-20090270279-A1 Materials and Methods for the Photodirected Synthesis of Oligonucleotide Arrays THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2009-10-29 US disclosed
US-7301049-B2 Photolabile esters and their uses THE INSTITUTE OF CANCER RESEARCH (GB) 2007-11-27 US disclosed
WO-2006117556-A2 MATERIALS AND METHODS FOR THE PHOTODIRECTED SYNTHESIS OF OLIGONUCLEOTIDE ARRAYS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2006-11-09 WO disclosed
US-20040242653-A1 Photolabile esters and their uses THE INSTITUTE OF CANCER RESEARCH (GB) 2004-12-02 US disclosed
EP-1399412-A1 PHOTOLABILE ESTERS AND THEIR USES The Institute of Cancer Research (GB) 2004-03-24 EP disclosed
WO-2003000644-A1 PHOTOLABILE ESTERS AND THEIR USES THE INSTITUTE OF CANCER RESEARCH (GB) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242653-A1 Photolabile esters and their uses DIMT1, DCTD, DTYMK LMNA 214/4885MEN1 2062/4885KMT2A 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.